Corcept Therapeutics Announces First Quarter 2016 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update

MENLO PARK, CA--(Marketwired - May 3, 2016) - Corcept Therapeutics Incorporated ( NASDAQ : CORT )

  • First quarter revenue of $16.1 million, a 59 percent increase from the first quarter of 2015
  • Excluding non-cash expenses, first quarter non-GAAP net income of $0.02 per share, compared to a non-GAAP net loss of $0.03 per share in the first quarter of 2015
  • GAAP breakeven in the first quarter of 2016, compared to a GAAP net loss of $0.05 per share in the first quarter of 2015
  • Cash balance at March 31 increases to $40.7 million
  • Company reiterates 2016 revenue guidance of $76-81 million
  • Results expected at mid-year 2016 in Phase 1/2 trial of mifepristone in combination with eribulin to treat triple-negative breast cancer (TNBC)
  • Recruitment underway in Phase 1/2 trial of selective cortisol modulator CORT125134 in combination with nab-paclitaxel to treat solid-tumor cancers
  • Phase 2 trial of CORT125134 to treat patients with Cushing's syndrome expected to start in the second quarter of 2016
  • Selective cortisol modulators CORT118335, CORT122928 and CORT125281 advance towards Phase 1

Corcept Therapeutics Incorporated ( NASDAQ : CORT ), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today reported its financial results for the quarter ended March 31, 2016.

Corcept reported revenue of $16.1 million and a GAAP net loss of $0.00 per share for the first quarter of 2016, compared to revenue of $10.1 million and a GAAP net loss of $0.05 per share in the first quarter of 2015. The company's cash and cash equivalents were $40.7 million at year-end, an increase of $300,000 from December 31, 2015.

The company reiterated its 2016 revenue guidance of $76-81 million.

"Corcept's business model continues to prove itself," said Dr. Joseph K. Belanoff, Corcept's Chief Executive Officer. "Our Cushing's syndrome franchise remains on track to generate $76-81 million in revenue this year, which will fully support the planned advancement of our cortisol modulation platform. It is gratifying to see our discovery program, which has identified so many promising compounds, mature into a development program with the potential to produce treatments for a wide range of serious diseases."

"The breadth of the clinical program we're building is impressive," added Robert S. Fishman, M.D., Corcept's Chief Medical Officer. "In the coming months, we expect results from our Phase 2A trial of mifepristone in combination with eribulin to treat TNBC. CORT125134, which has already produced promising pre-clinical and Phase 1 results, has entered Phase 1/2 as a treatment for patients with a range of solid-tumor cancers and this quarter we plan for it to start Phase 2 as a treatment for Cushing's syndrome. Equally exciting, more selective cortisol modulators are advancing towards the clinic. These compounds have shown promise in animal models of a wide range of serious diseases, including oncologic disorders, fatty liver disease, antipsychotic induced weight gain and alcoholism."

Financial Discussion Corcept's GAAP net loss in the first quarter of 2016 was $19,000, compared to a GAAP net loss of $4.8 million in the first quarter of 2015. Excluding non-cash expenses related to stock-based compensation and accreted interest on the company's capped royalty obligation (the "Royalty Financing"), Corcept generated $2.2 million of non-GAAP net income in the first quarter, compared to a non-GAAP net loss of $2.7 million in the first quarter of 2015. A reconciliation of GAAP to non-GAAP net operating results is set forth below.

Operating expenses for the first quarter increased to $15.5 million, from $14.1 million in the first quarter of 2015, primarily due to increases in patient support costs, compensation and professional services costs associated with our expanded field sales force, the additional distribution expense resulting from higher sales volumes, and increased spending on the clinical development of CORT125134.

Corcept's cash and cash equivalents totaled $40.7 million as of March 31, 2016, compared to $40.4 million as of December 31, 2015. These cash balances reflect Corcept's scheduled payments due under the Royalty Financing. Pursuant to the terms of the agreement, Corcept paid $3.0 million in the first quarter of 2016, compared to $2.8 million in the fourth quarter of 2015. Corcept expects to make its final payment under the Royalty Financing in 2017.

Conference Call Corcept will hold a conference call on May 3, 2016, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss this announcement. To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 42398569. A replay will be available through May 17, 2016 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode is 42398569.

About Cushing's Syndrome Endogenous Cushing's syndrome is caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol and is generated by tumors that produce cortisol or ACTH. Cushing's syndrome is an orphan indication that most commonly affects adults aged 20-50. An estimated 10-15 of every one million people are newly diagnosed with this syndrome each year, resulting in over 3,000 new patients annually in the United States. An estimated 20,000 patients in the United States have Cushing's syndrome. Symptoms vary, but most people have one or more of the following manifestations: high blood sugar, diabetes, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are also common. Cushing's syndrome can affect every organ system in the body and can be lethal if not treated effectively.

About Triple-Negative Breast Cancer (TNBC) TNBC is a form of the disease in which the three receptors that fuel most breast cancer growth -- estrogen, progesterone and the HER-2/neu gene -- are not present. Because the tumor cells lack the necessary receptors, treatments that target estrogen, progesterone and HER-2 receptors are ineffective. In 2013, approximately 40,000 women were diagnosed with TNBC. We estimate that more than 75 percent of these women's tumor cells expressed the GR receptor to which cortisol binds. There is no FDA-approved treatment and neither a targeted treatment nor an approved standard chemotherapy regimen for relapsed TNBC patients exists.

About Korlym ® Korlym modulates the effect of cortisol at GR, one of the two receptors to which cortisol binds, thereby inhibiting the effects of excess cortisol in patients with Cushing's syndrome. Since 2012, Corcept has made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym was the first FDA-approved treatment for that illness and the FDA has designated it as an Orphan Drug for that indication.

About CORT125134 CORT125134 is the lead compound in Corcept's portfolio of selective cortisol modulators. It is a non-steroidal competitive antagonist of GR that does not bind to the body's other hormone receptors, including the progesterone receptor. It is the affinity of Korlym for the progesterone receptor that results in termination of pregnancy and can cause endometrial thickening and irregular vaginal bleeding in some women. CORT125134 will not have these effects. The compound is proprietary to Corcept and is protected by composition of matter and method of use patents extending into 2033.

About Corcept Therapeutics Incorporated Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym, a first-generation cortisol modulator, is the company's first FDA-approved medication. The company is conducting a Phase 1/2 trial of mifepristone for the treatment of TNBC and has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of metabolic, oncologic and psychiatric disorders. It also holds composition of matter patents covering its selective cortisol modulators.

Non-GAAP Measures of Net Income and Loss To supplement Corcept's financial results presented on a GAAP basis, we use non-GAAP measures of net income and net loss that exclude non-cash stock-based compensation expense and interest expense related to our capped royalty financing transaction. We believe that these non-GAAP measures help investors better evaluate the company's past financial performance and potential future results. Non-GAAP measures should not be considered in isolation or as a substitute for comparable GAAP accounting and investors should read them in conjunction with the company's financial statements prepared in accordance with GAAP. The non-GAAP measures of net income and net loss and net income and net loss per share that we use may be different from, and not directly comparable to, similarly titled measures used by other companies.

Forward-Looking Statements Statements made in this press release, other than statements of historical fact, are forward-looking statements. These forward-looking statements, including statements regarding anticipated future net revenues, the timing of clinical trials and clinical trial results and the advancement of clinical trials, are subject to known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements, including the pace of Korlym's acceptance by physicians and patients, the pace of enrollment in or the outcome of the company's Phase 1/2 study of mifepristone in the treatment of TNBC, its planned Phase 2 studies of CORT125134, the effects of rapid technological change and competition, the protections afforded by Korlym's Orphan Drug designation or by Corcept's other intellectual property rights, or the cost, pace and success of Corcept's other product development efforts. These and other risks are set forth in the company's SEC filings, which are available at the company's website ( www.corcept.com ) or from the SEC's website ( www.sec.gov ). Corcept disclaims any intention or duty to update any forward-looking statement made in this press release.

 
 
CORCEPT THERAPEUTICS INCORPORATED
CONDENSED BALANCE SHEETS
(in thousands)
 
    March 31, 2016   December 31, 2015
   
    (Unaudited)   (Note)
             
ASSETS:            
  Cash and cash equivalents   $ 40,744   $ 40,435
  Trade receivables     6,752     6,221
  Inventory     4,192     4,482
  Other assets     1,224     764
    Total assets   $ 52,912   $ 51,902
             
LIABILITIES AND STOCKHOLDERS' EQUITY:            
  Accounts payable   $ 2,082   $ 1,325
  Long-term obligation     25,041     27,493
  Other liabilities     5,621     4,586
  Stockholders' equity     20,168     18,498
    Total liabilities and stockholders' equity   $ 52,912   $ 51,902
                 

Note: Derived from audited financial statements at that date.

   
   
CORCEPT THERAPEUTICS INCORPORATED  
CONDENSED STATEMENTS OF OPERATIONS  
(in thousands, except per share amounts)  
   
(Unaudited)  
   
    Three Months Ended March 31,  
             
    2016     2015  
                 
Revenues:                
  Product revenue, net   $ 16,061     $ 10,102  
                 
Operating expenses:                
  Cost of sales     403       302  
  Research and development     4,634       4,377  
  Selling, general and administrative     10,432       9,453  
    Total operating expenses     15,469       14,132  
Income (loss) from operations     592       (4,030 )
Interest and other expense     (611 )     (800 )
                 
Net loss   $ (19 )   $ (4,830 )
                 
Basic and diluted net loss per share   $ (0.00 )   $ (0.05 )
                 
Shares used in computing basic and diluted net loss per share     109,661       101,905  
                 
   
   
CORCEPT THERAPEUTICS INCORPORATED  
RECONCILIATION OF GAAP TO NON-GAAP NET LOSS  
(in thousands, except per share amounts)  
   
(Unaudited)  
    Three Months Ended March 31,  
             
    2016     2015  
                 
GAAP net loss   $ (19 )   $ (4,830 )
                 
Non-cash expenses:                
  Stock-based compensation                
    Research and development     286       205  
    Selling, general and administrative     1,327       1,204  
      Total stock-based compensation     1,613       1,409  
  Accretion of interest expense related to long-term obligation     584       762  
Non-GAAP net income (loss), as adjusted for non-cash expenses   $ 2,178     $ (2,659 )
                 
                 
GAAP basic and diluted net loss per share   $ (0.00 )   $ (0.05 )
                 
Non-GAAP basic and diluted net income (loss) per share, as adjusted for non-cash expenses   $ 0.02     $ (0.03 )
                 
Shares used in computing basic and diluted net income (loss) per share     109,661       101,905  

CONTACT: Charles Robb Chief Financial Officer Corcept Therapeutics 650-688-8783 Email Contact www.corcept.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 165

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 98

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Radnostix Sees Mixed Results, Plans Strategic Shift

Updated Category News Views 90

Radnostix: A Rocky Third Quarter with Glimmers of Hope Alright, sit back and digest this: Radnostix, the company once known as International Isotopes Inc., is currently in the midst of a renovation of sorts. They just reported their financial results for the third quarter of 2026, and honestly, they're a mixed bag. Revenue Falls but Theranostics Shines Quarterly revenue...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 133

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
League's AI Launch: A New Era in Healthcare

Updated Category News Views 76

AI: Healthcare's Bold New Move Ah, here we go. Another tech jump in healthcare. This time it's the folks over at League, stirring the pot with some new AI gimmicks. They've slapped together what they call an 'AI Front Door' and an 'AI Care Companion'—part of their Forge by League platform. Now, if there's one thing we know, it's that the healthcare sector loves a good...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 126

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 165

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 69

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 120

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading

Top 5 Most Recently Viewed Articles

Trua: Veteran-Led Service Offers Senior Living Help

Updated Category News Views 31

A New Chapter for Senior Living Guidance Life's complexities can be as tough as a two-dollar steak, and let's face it, senior living decisions often top that chart. Greater Boston gets a new lifeline with Trua of Greater Boston breaking into the scene. Not just any placement service, mind you. Run by Jersouk Touy and Jessie Marasco, it promises a blend of personalized,...

Continue Reading
Standex International Corporation Reports Q4 Fiscal 2025 Results

Updated Category News Views 162

Standex International Corporation to Announce Q4 2025 Results Standex International Corporation (NYSE: SXI) is set to unveil its financial results for the fourth quarter of fiscal year 2025 on Thursday. The report will be released after the market closes, providing investors and stakeholders with key insights into the company's performance. Key Details of the Announcement...

Continue Reading
Ireland's €3 Billion Bond Sale Highlights Strong Investor Demand

Updated Category News Views 136

Overview of Ireland's Successful Bond Issuance Dublin has recently seen an impressive move in the financial markets with the National Treasury Management Agency successfully issuing €3 billion in 30-year fixed-rate notes. This significant bond issuance demonstrates the strong appetite from investors without the need for stabilization measures, reflecting confidence in...

Continue Reading
Exciting Developments in Yukon Metals' Birch Copper-Gold Project

Updated Category News Views 196

Significant Updates from the Birch Copper-Gold Project Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) has recently announced thrilling developments concerning its 100%-owned Birch Copper-Gold Project, spanning 7,000 hectares. This project is located approximately 65 kilometres from Burwash Landing and 200 kilometres from Whitehorse. The current drill program aims...

Continue Reading
Krystal Biotech's Upcoming Presentation at Major Healthcare Event

Updated Category News Views 122

Krystal Biotech Set to Attend Major Healthcare Conference Krystal Biotech, Inc. (NASDAQ: KRYS), a company dedicated to leading the way in genetic medicine, has shared an exciting opportunity for both investors and the public. The Company will highlight its latest advancements at the upcoming 2024 Cantor Global Healthcare Conference in New York. This event stands out as...

Continue Reading